Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 27;14(10):1030.
doi: 10.3390/jpm14101030.

The Role of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Renal Cell Carcinoma (RCC) Treated with ICIs-TKIs: A Retrospective Multicentric Study

Maria La Vecchia  1 , Manuela Federico  1 , Dario Aiello  1 , Valentina Zagardo  2 , Antonella Mazzonello  1 , Lorella Testa  1 , Leonarda La Paglia  1 , Tiziana Bruno  1 , Ivan Fazio  1
Affiliations

The Role of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Renal Cell Carcinoma (RCC) Treated with ICIs-TKIs: A Retrospective Multicentric Study

Maria La Vecchia et al. J Pers Med. .

Abstract

Background: This multicentric, retrospective study investigated the use of stereotactic body radiotherapy (SBRT) in patients (pts) with metastatic renal cell carcinoma (mRCC) who experienced oligoprogression during a combination therapy with an immune checkpoint inhibitor (ICI) and a tyrosine-kinase inhibitor (TKI).

Methods: We retrospectively evaluated 34 pts affected by oligoprogressive RCC treated with an ICI-TKI combination between January 2020 and December 2023. SBRT was delivered to each site of oligoprogressive metastatic disease. After SBRT, pts were given follow-up clinical evaluations. 6-12-18-month local control (LC) rates and median next-line treatment-free survival (NEST-FS) were the primary endpoints. The secondary endpoints were overall response rate (ORR), clinical benefits and safety.

Results: After a median follow-up of 24 months, 6-12-18-month LC rates were 100%, 71% and 43%, respectively, and the median NEST-FS was 20 months. ORR was 90%, while clinical benefit was 100%. No > G2 adverse events related to SBRT were recorded.

Conclusions: In our study, SBRT for oligoprogressive mRCC turned out to be a safe and useful treatment which was able to preserve current treatment. Further prospective studies are necessary to explore the effects of the ICIs-TKIs combination and SBRT upon oligoprogressive sites in mRCC.

Keywords: immunotherapy; renal cell carcinoma; stereotactic body radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles

References

    1. Tomoyuki M., Suguru K. Epidemiology and Prevention of Renal Cell Carcinoma. Cancers. 2022;14:4059. doi: 10.3390/cancers14164059. - DOI - PMC - PubMed
    1. Motzer R.J., Hutson T.E. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009;27:3584–3590. doi: 10.1200/JCO.2008.20.1293. - DOI - PMC - PubMed
    1. LINEE GUIDA AIOM 2021
    1. Rabinovitch R.A., Zelefsky M.J. Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy. J. Clin. Oncol. 1994;12:206–212. doi: 10.1200/JCO.1994.12.1.206. - DOI - PubMed
    1. Kim S.P., Weight C.J. Outcomes and clinico pathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology. 2011;78:1101–1106. doi: 10.1016/j.urology.2011.05.012. - DOI - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources

  NODES
twitter 2